Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2018.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has entered into an R&D loan facility agreement with Paddington St Finance. The maximum loan value of the facility is the lesser of $2 million or 80% of the estimated refundable tax offset credits under the ATO's R&D tax incentive.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Half-Year Report for the 6 months to 31 December 2017.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Progenza has been granted an Advanced Therapy Medicinal Product classification by the Committee for Advanced Therapies of the European Medicines Agency, following consultation with the European Commission.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
